Formestane is a new aromatase inhibitor used as second-line endocrine treatment for postmenopausal women with advanced breast cancer. The most frequent side effects are local reactions. Here we report the development of immune thrombocytopenia coinciding with administration of this drug.
Figures & Tables
Article Information
Vol. 83 No. 10 (1998): October, 1998 : Case Reports
Published
1998-01-01
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
Article Usage
Online Views
121
PDF Downloads
85
Statistics from Altmetric.com
No Data
How to Cite
1.
I Espanol, E Muniz-Diaz, MC Alonso, N Pujol-Moix. Severe immune thrombocytopenia during formestane treatment. Haematologica 1998;83(10):953-954; https://doi.org/10.3324/%x.
To create an adaptation, translation, or derivative of the
original work, for commercial e-prints and printed articles further permission is
required. For
information contact: marketing@haematologica.org
Other types of copyright management, can be agreed with the Editorial office.
